Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Chemomab Therapeutics Ltd. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- +4 vs. Q3 2025
- Shares held
- 367.4K
- −22.9K (−5.9%) vs. Q3 2025
- Total value
- $606.1K
- −$420.4K (−41.0%) vs. Q3 2025
- New holders
- 6
- 4 more added
- Sold out
- 2
- 3 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $615.3K |
| Q1 2026 | 15 | $551.9K |
| Q4 2025 | 14 | $606.1K |
| Q3 2025 | 10 | $1.03M |
| Q2 2025 | 14 | $4.91M |
| Q1 2025 | 17 | $4.07M |
| Q4 2024 | 16 | $7.53M |
| Q3 2024 | 15 | $7.14M |
| Q2 2024 | 15 | $2.44M |
| Q1 2024 | 14 | $2.07M |
| Q4 2023 | 16 | $1.43M |
| Q3 2023 | 11 | $2.26M |
| Q2 2023 | 11 | $3.33M |
| Q1 2023 | 13 | $4.56M |
| Q4 2022 | 14 | $10.6M |
| Q3 2022 | 15 | $8.09M |
| Q2 2022 | 13 | $12.2M |
| Q1 2022 | 15 | $15.9M |
| Q4 2021 | 14 | $22.7M |
| Q3 2021 | 15 | $35.9M |
| Q2 2021 | 12 | $58.7M |
| Q1 2021 | 10 | $82.6M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Chemomab Therapeutics Ltd.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 103,781 | $171.2K | 0.00% | +103,781 | New |
| ADAR1 Capital Management, LLC | 80,000 | $132.0K | 0.01% | +80,000 | New |
| Ikarian Capital, LLC | 51,793 | $85.5K | 0.01% | −1,469−2.8% | Reduced |
| Kestra Private Wealth Services, LLC | 51,710 | $85.3K | 0.00% | +51,710 | New |
| XTX Topco Ltd | 19,013 | $31.4K | 0.00% | +19,013 | New |
| Rhumbline Advisers | 17,856 | $29.5K | 0.00% | +8,351+87.9% | Added |
| Jane Street Group, LLC | 15,598 | $25.7K | 0.00% | −5,913−27.5% | Reduced |
| Virtu Financial LLC | 10,933 | $18.0K | 0.00% | +10,933 | New |
| BNP Paribas Arbitrage, SA | 8,125 | $13.4K | 0.00% | +2,375+41.3% | Added |
| Morgan Stanley | 3,775 | $6.23K | 0.00% | −86,290−95.8% | Reduced |
| GAMMA Investing LLC | 2,514 | $4.15K | 0.00% | +1,847+276.9% | Added |
| UBS Group AG | 2,253 | $3.72K | 0.00% | +2,154+2,175.8% | Added |
| SBI Securities Co., Ltd. | 26 | $43 | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 2 | $3 | 0.00% | +2 | New |
| Sphera Funds Management Ltd. | 0 | $0 | 0.00% | −179,425−100.0% | Sold out |
| Stonepine Capital Management, LLC | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |